Table 3.
Percentage of peripheral blood lymphocytes expressing interleukin (IL)-12 receptor β2 detected with flow cytometry, ratio of mRNA/rRNA in peripheral blood mononuclear cells quantified using real-time polymerase chain reaction (PCR) and cytokine secretion detected with enzyme-linked immunospot or enzyme-linked immunosorbent assay.
| Chronic LB | Subacute LB | Asymptomatic | Healthy control | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | Median (min–max) | n | Median (min–max) | n | Median (min–max) | n | Median (min–max) | ||
| Cell phenotype | Antigen | ||||||||
| CD3+ | PHA | 9 | 4·3 (0·0–14·0) | 8 | 0·4 (− 0·2–33·3) | 6 | 3·0 (0·2–12·1) | 8 | 2·5 (0·0–10·2) |
| CD4+ | PHA | 9 | 2·9 (0·2–13·7) | 8 | 0·2 (− 0·4–39·7) | 6 | 4·1 (0·1–13·5) | 8 | 3·7 (0·6–11·0) |
| CD8+ | PHA | 9 | 2·9 (− 0·3–6·9) | 8 | 1·7 (0·6–26·5) | 6 | 0·3 (0·0–9·5) | 8 | 1·3 (− 0·5–6·0) |
| CD56+ | PHA | 9 | 0·9 (− 0·4–8·3) | 7 | − 0·2 (− 0·9–26·2) | 5 | 0·3 (0·0–2·6) | 8 | 1·7 (0·0–4·2) |
| mRNA | Antigen | ||||||||
| IL-12Rβ2 | OF | 9 | 0·3 (− 1·1–3·0) | 13 | 0·5 (0·1–4·7) | 13 | 0·2 (− 1·5–2·6) | 12 | 0·1 (− 0·3–9·7) |
| PHA | 10 | 9·2 (0·3–66·1) | 13 | 1·2 (0·2–21·6) | 13 | 4·4 (0·2–66·7) | 13 | 2·2 (0·4–60·7) | |
| PPD | 3 | 2·6 (0·9–4·7) | 9 | 1·1 (0·1–14·3) | 9 | 1·2 (− 1·8–1·8) | 7 | 2·2 (0·0–37·2) | |
| FoxP3 | PHA | 10 | 1·3 (− 1·8–7·2) | 13 | 1·8 (0·7–12·1) | 13 | 2·5 (0·8–8·6) | 13 | 1·7 (0·7–11·9) |
| PPD | 3 | 1·0 (0·9–2·5) | 9 | 0·6 (− 5·7–2·0) | 9 | 0·2 (− 4·8–1·4) | 7 | − 0·8 (− 4·6–1·5) | |
| Antigen | Cytokine | ||||||||
| OF (ELISPOT) | IL-4 | 9 | 2·0 (− 5·6–36·2) | 9 | 0·9 (− 7·4–4) | 12 | 2·2 (− 3·3–24·2) | 13 | ·0 (− 14·7–3·7) |
| IL-5 | 7 | 3·9 (− 3·2–40·6) | 7 | 1·4 (− 7·3–17·8) | 4 | 10·9 (− 9·2–56·5) | 4 | 2·6 (2·0–11·0) | |
| IL-10 | 9 | 323·5 (− 33·5–821·7) | 6 | 109·3 (20·5–1063·3) | 6 | 325·3 (9·0–962·4) | 7 | 236·0 (4·1–956·2) | |
| IL-13 | 7 | 2·3 (− 0·7–20·7) | 5 | −· 0·5 (− 6·2–15·6) | 4 | 4·0 (− 82·8–19·6) | 4 | − · 0·2 (− 2·3–4·0) | |
| OF (ELISA) | IFN-γ | 11 | 177·9 (− 37·0–1111·8) | 11 | 88·4 (− 5·4–544·1) | 13 | 67·7 (− 273·8–1013·5) | 12 | 106·1 (− 1102·7–943·8) |
| IL-5 | 11 | ·0 (− 8·1–27·7) | 11 | ·0 (− 11·1–10·2) | 13 | 0·6 (− 43·6–25·0) | 12 | ·0 (− 4·2–35·7) | |
| IL-10 | 11 | 61·2 (37·7–170·0) | 11 | 59·5 (4·8–153·8) | 13 | 58·0 (3·9–443·1) | 12 | 110·0 (− 6·3–646·6) | |
| PPD (ELISA) | IFN-γ | 5 | 5099·5 (920·6–27846·1) | 7 | 4913·5 (133·3–28650·0) | 10 | 1841·8 (82·2–23320·1) | 9 | 4461·0 (− 181·0–52009·7) |
| IL-5 | 5 | 9·4 (− 1·6–60·8) | 7 | 16·7 (− 6·0–43·7) | 10 | 9·9 (− 29·6–52·1) | 9 | ·0 (− 4·2–21) | |
| IL-10 | 5 | 27·7 (26·8–45·1) | 7 | 32·0 (4·6–76·5) | 10 | 23·5 (10·7–67·5) | 9 | 68·2 (− 21·1–249·0) | |
| PHA (ELISA) | IFN-γ | 11 | 627·5 (39·1–14322·7) | 11 | 1176·9 (29·0–8047·9) | 13 | 2543·4 (46·8–5899·2) | 13 | 574·9 (17·6–4039·4) |
| IL-5 | 12 | 61·4 (10–159·3) | 11 | 30·8 (4·1–485·2) | 13 | 40·0 (3·9–510·0) | 13 | 5·3 (0–164·5) | |
| IL-10 | 12 | 250·8 (41·3–435·4) | 11 | 294·1 (24·7–1207·6) | 13 | 309·6 (42·6–716·1) | 13 | 264·3 (73·3–674·7) | |
LB, Lyme borreliosis; PHA, phytohaemagglutinin; OF, outer surface protein enriched fraction of Borrelia garinii strain Ip90; PPD, purified protein derivate of tuberculin; Fox, forkhead box; IL, interleukin; IFN, interferon.